Loading...

We've got a brand new version of Simply Wall St! Try it out

Eurolife Brands

CNSX:EURO
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EURO
CNSX
CA$35M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Eurolife Brands Inc. operates as a business technology company within the health sciences sector in the United States and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Eurolife Brands has significant price volatility in the past 3 months.
EURO Share Price and Events
7 Day Returns
-4.8%
CNSX:EURO
1.6%
CA Healthcare Services
0.7%
CA Market
1 Year Returns
11.1%
CNSX:EURO
-55.6%
CA Healthcare Services
-0.5%
CA Market
EURO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eurolife Brands (EURO) -4.8% -23.1% 56.9% 11.1% - -
CA Healthcare Services 1.6% 1.1% -3.2% -55.6% -25.9% 45.7%
CA Market 0.7% 2.1% 1.2% -0.5% 8% 0.7%
1 Year Return vs Industry and Market
  • EURO outperformed the Healthcare Services industry which returned -55.6% over the past year.
  • EURO outperformed the Market in Canada which returned -0.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

EURO Value

 Is Eurolife Brands undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Eurolife Brands is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Eurolife Brands has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Eurolife Brands. This is due to cash flow or dividend data being unavailable. The share price is CA$0.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eurolife Brands's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eurolife Brands's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:EURO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.04
CNSX:EURO Share Price ** CNSX (2019-09-13) in CAD CA$0.1
North America Healthcare Services Industry PE Ratio Median Figure of 13 Publicly-Listed Healthcare Services Companies 61.61x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eurolife Brands.

CNSX:EURO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:EURO Share Price ÷ EPS (both in CAD)

= 0.1 ÷ -0.04

-2.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurolife Brands is loss making, we can't compare its value to the North America Healthcare Services industry average.
  • Eurolife Brands is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Eurolife Brands's expected growth come at a high price?
Raw Data
CNSX:EURO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 2.43x
Canada Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 0.93x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eurolife Brands, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eurolife Brands's assets?
Raw Data
CNSX:EURO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.00
CNSX:EURO Share Price * CNSX (2019-09-13) in CAD CA$0.1
Canada Healthcare Services Industry PB Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 1.57x
Canada Market PB Ratio Median Figure of 2,453 Publicly-Listed Companies 1.45x
CNSX:EURO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:EURO Share Price ÷ Book Value per Share (both in CAD)

= 0.1 ÷ 0.00

-2173.91x

* Primary Listing of Eurolife Brands.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurolife Brands has negative assets, we can't compare the value of its assets to the CA Healthcare Services industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Eurolife Brands's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Healthcare Services industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Eurolife Brands's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Eurolife Brands has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EURO Future Performance

 How is Eurolife Brands expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eurolife Brands has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.9%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eurolife Brands expected to grow at an attractive rate?
  • Unable to compare Eurolife Brands's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Eurolife Brands's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Eurolife Brands's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:EURO Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 27.9%
North America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 13%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.3%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:EURO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:EURO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -2 -6
2019-03-31 0 -4 -6
2018-12-31 0 -2 -5
2018-09-30 0 -4 -4
2018-06-30 0 -2 -2
2018-03-31 -1 -1
2017-12-31 0 -1
2017-09-30 0 0 0
2017-06-30 0 0 0
2017-03-31 0 0 0
2016-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Eurolife Brands is high growth as no earnings estimate data is available.
  • Unable to determine if Eurolife Brands is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:EURO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Eurolife Brands Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:EURO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.03
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eurolife Brands will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Eurolife Brands's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Eurolife Brands's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Eurolife Brands's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eurolife Brands has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EURO Past Performance

  How has Eurolife Brands performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eurolife Brands's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eurolife Brands does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Eurolife Brands's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Eurolife Brands's 1-year growth to the North America Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Eurolife Brands's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eurolife Brands Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:EURO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.02 -6.34 6.32
2019-03-31 0.14 -5.99 6.13
2018-12-31 0.13 -4.74 4.93
2018-09-30 0.14 -3.61 3.75 -0.05
2018-06-30 0.12 -1.78 1.89 -0.04
2018-03-31 -0.88 0.88 -0.02
2017-12-31 -0.51 0.51
2017-09-30 0.00 -0.27 0.00 0.26
2017-06-30 0.00 -0.26 0.00 0.25
2017-03-31 0.00 -0.24 0.00 0.23
2016-12-31 0.14 -0.26 0.06 0.21
2015-12-31 0.01 -0.14 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Eurolife Brands has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Eurolife Brands has efficiently used its assets last year compared to the North America Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Eurolife Brands improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Eurolife Brands's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eurolife Brands has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EURO Health

 How is Eurolife Brands's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eurolife Brands's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eurolife Brands's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Eurolife Brands has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eurolife Brands's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Eurolife Brands has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eurolife Brands Company Filings, last reported 2 months ago.

CNSX:EURO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -0.01 0.14
2019-03-31 0.74 0.00 0.36
2018-12-31 0.41 0.00 0.22
2018-09-30 1.32 0.00 0.78
2018-06-30 1.36 0.00 1.20
2018-03-31 0.81 0.00 0.86
2017-12-31 1.18 0.00 1.23
2017-09-30 -0.40 0.00
2017-06-30 -0.39 0.00
2017-03-31 -0.37 0.00
2016-12-31 -0.35 0.00
2015-12-31 -0.09 0.00 0.01
  • Eurolife Brands has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Eurolife Brands's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Eurolife Brands has less than a year of cash runway based on current free cash flow.
  • Eurolife Brands has less than a year of cash runway if free cash flow continues to grow at historical rates of 109.6% each year.
X
Financial health checks
We assess Eurolife Brands's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eurolife Brands has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EURO Dividends

 What is Eurolife Brands's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eurolife Brands dividends.
If you bought CA$2,000 of Eurolife Brands shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eurolife Brands's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eurolife Brands's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:EURO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 1%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eurolife Brands has not reported any payouts.
  • Unable to verify if Eurolife Brands's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eurolife Brands's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eurolife Brands has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eurolife Brands's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eurolife Brands afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eurolife Brands has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EURO Management

 What is the CEO of Eurolife Brands's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shawn Moniz
CEO Bio

Mr. Shawn Moniz serves as the Chief Executive Officer and a Director of Cannvas MedTech Inc. As Chief Executive Officer, Mr. Moniz leads Cannvas MedTech Inc.’s strategic direction and overall firm-wide success. Mr. Moniz has over 19+ years’ experience in strategic CRM brand positioning and loyalty focus, marketing automation, digital data strategy and omni-channel data driven marketing. Being an exceptional strategic marketing technologist, he has a multitude of disciplinary backgrounds which have enabled him to take on significant roles in the leading the vision, innovation, growth strategy all while demonstrating excellent leadership and mentorship to junior team members. With his wealth of corporate leadership experience and technological expertise, Mr. Moniz enables Cannvas MedTech Inc. to establish a dominant presence in the growing cannabis economy. He recently served in the capacity of Senior Director of Strategic Solutions across three organizations including Klick Inc., where he delivered strategic CRM solutions to numerous Fortune 500 companies with clients such as Astellas, Takeda, Abbvie, Shire, Novartis, Novo Nordisk, UCB, NBA, Air Canada, John Hancock, Yum! Brands (Taco Bell, Pizza Hut, KFC), Pitney Bowes, Tim Hortons and Kraft US / Canada, Astra Zeneca and XM Sirius Radio.

CEO Compensation
  • Insufficient data for Shawn to compare compensation growth.
  • Insufficient data for Shawn to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Shawn Moniz

TITLE
CEO & Director

Miroslav Beganovic

TITLE
Chief Financial Officer
TENURE
1.4 yrs

Steve Loutskou

TITLE
Chief Operating Officer of Global Markets & Director

Radu Puscasu

TITLE
Vice President of Technology

Marco Contardi

TITLE
Director & Corporate Counsel
Board of Directors Tenure

Average tenure of the Eurolife Brands board of directors in years:

1.1
Average Tenure
  • The average tenure for the Eurolife Brands board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shawn Moniz

TITLE
CEO & Director

Steve Loutskou

TITLE
Chief Operating Officer of Global Markets & Director

Marco Contardi

TITLE
Director & Corporate Counsel
TENURE
1.4 yrs

Derek Lloyd Ivany

TITLE
Chairman of the Advisory Board

Lindsay Hamelin

TITLE
Director
TENURE
1.4 yrs

Daniel Bal

TITLE
Member of the Medical Advisory Board
TENURE
1.2 yrs

Shirish Patel

TITLE
Member of the Medical Advisory Board
TENURE
1.1 yrs

Stacey Paterson

TITLE
Member of the Medical Advisory Board
TENURE
1.1 yrs

Angela Smith

TITLE
Member of Cannabis Sciences Advisory Board
TENURE
0.7 yrs

Emma Chasen

TITLE
Member of Cannabis Sciences Advisory Board
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Eurolife Brands individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
30. Aug 19 Buy Fusionworx Investment Group Inc. Company 27. Aug 19 29. Aug 19 414,000 CA$0.11 CA$42,644
22. Aug 19 Buy Fusionworx Investment Group Inc. Company 21. Aug 19 21. Aug 19 46,000 CA$0.10 CA$4,600
19. Aug 19 Buy Steve Loutskou Individual 16. Aug 19 16. Aug 19 32,900 CA$0.14 CA$4,441
16. Aug 19 Buy Fusionworx Investment Group Inc. Company 15. Aug 19 15. Aug 19 43,500 CA$0.13 CA$5,655
16. Aug 19 Buy FourOneSix Inc. Company 14. Aug 19 14. Aug 19 360,500 CA$0.14 CA$48,667
08. Aug 19 Buy Steve Loutskou Individual 07. Aug 19 07. Aug 19 5,800,000 CA$0.06 CA$333,498
08. Aug 19 Buy Shawn Moniz Individual 07. Aug 19 07. Aug 19 5,800,000 CA$0.06 CA$333,498
24. Jul 19 Buy Fusionworx Investment Group Inc. Company 15. Feb 19 03. Jul 19 2,848,000 CA$0.07 CA$159,452
17. Jul 19 Buy Lindsay Hamelin Individual 16. Jul 19 16. Jul 19 100,000 CA$0.05 CA$5,000
17. Jul 19 Buy Fusionworx Investment Group Inc. Company 16. Jul 19 16. Jul 19 500,000 CA$0.05 CA$25,000
17. Jul 19 Buy FourOneSix Inc. Company 16. Jul 19 16. Jul 19 500,000 CA$0.05 CA$25,000
25. Jan 19 Buy Lindsay Hamelin Individual 25. Jan 19 25. Jan 19 350,000 CA$0.07 CA$26,250
06. Mar 19 Buy FourOneSix Inc. Company 05. Mar 19 05. Mar 19 22,000 CA$0.06 CA$1,292
15. Feb 19 Buy Fusionworx Investment Group Inc. Company 13. Feb 19 15. Feb 19 56,000 CA$0.07 CA$3,790
15. Feb 19 Buy FourOneSix Inc. Company 13. Feb 19 14. Feb 19 92,000 CA$0.07 CA$6,218
13. Feb 19 Buy FourOneSix Inc. Company 11. Feb 19 11. Feb 19 52,000 CA$0.07 CA$3,750
07. Feb 19 Buy FourOneSix Inc. Company 04. Feb 19 06. Feb 19 410,000 CA$0.08 CA$31,892
01. Feb 19 Buy Fusionworx Investment Group Inc. Company 30. Jan 19 30. Jan 19 154,000 CA$0.07 CA$10,738
01. Feb 19 Buy FourOneSix Inc. Company 30. Jan 19 31. Jan 19 50,000 CA$0.07 CA$3,663
21. Jan 19 Buy Miroslav Beganovic Individual 21. Jan 19 21. Jan 19 66,668 CA$0.08 CA$5,000
21. Jan 19 Buy Fusionworx Investment Group Inc. Company 21. Jan 19 21. Jan 19 2,000,000 CA$0.08 CA$150,000
21. Jan 19 Buy FourOneSix Inc. Company 21. Jan 19 21. Jan 19 2,000,000 CA$0.08 CA$150,000
14. Jan 19 Buy Shawn Moniz Individual 10. Jan 19 10. Jan 19 8,000 CA$0.08 CA$640
11. Jan 19 Buy FourOneSix Inc. Company 10. Jan 19 10. Jan 19 78,000 CA$0.08 CA$6,142
09. Jan 19 Buy FourOneSix Inc. Company 08. Jan 19 08. Jan 19 120,000 CA$0.08 CA$9,395
01. Jan 19 Buy FourOneSix Inc. Company 27. Dec 18 27. Dec 18 8,000 CA$0.07 CA$580
28. Dec 18 Buy Shawn Moniz Individual 24. Dec 18 24. Dec 18 17,872 CA$0.06 CA$1,117
25. Dec 18 Buy FourOneSix Inc. Company 19. Dec 18 19. Dec 18 126,000 CA$0.07 CA$8,000
13. Dec 18 Buy FourOneSix Inc. Company 11. Dec 18 11. Dec 18 6,000 CA$0.08 CA$472
10. Dec 18 Buy FourOneSix Inc. Company 07. Dec 18 07. Dec 18 92,000 CA$0.07 CA$6,410
07. Dec 18 Buy Shawn Moniz Individual 06. Dec 18 06. Dec 18 60,000 CA$0.06 CA$3,750
07. Dec 18 Buy Fusionworx Investment Group Inc. Company 06. Dec 18 06. Dec 18 160,000 CA$0.06 CA$10,000
06. Dec 18 Buy Shawn Moniz Individual 05. Dec 18 05. Dec 18 36,000 CA$0.07 CA$2,377
05. Dec 18 Buy Shawn Moniz Individual 04. Dec 18 04. Dec 18 40,000 CA$0.07 CA$2,868
03. Dec 18 Buy Shawn Moniz Individual 03. Dec 18 03. Dec 18 12,000 CA$0.08 CA$945
26. Nov 18 Buy FourOneSix Inc. Company 26. Nov 18 26. Nov 18 100,000 CA$0.08 CA$8,250
19. Nov 18 Buy Fusionworx Investment Group Inc. Company 19. Nov 18 19. Nov 18 100,000 CA$0.08 CA$8,375
22. Nov 18 Buy Steve Loutskou Individual 22. Nov 18 22. Nov 18 24,000 CA$0.08 CA$1,860
22. Nov 18 Buy FourOneSix Inc. Company 22. Nov 18 22. Nov 18 66,000 CA$0.08 CA$5,275
21. Nov 18 Buy Fusionworx Investment Group Inc. Company 21. Nov 18 21. Nov 18 28,000 CA$0.08 CA$2,292
20. Nov 18 Buy Shawn Moniz Individual 20. Nov 18 20. Nov 18 24,000 CA$0.08 CA$1,945
20. Nov 18 Buy Fusionworx Investment Group Inc. Company 20. Nov 18 20. Nov 18 3,000,000 CA$0.08 CA$236,250
14. Nov 18 Buy FourOneSix Inc. Company 14. Nov 18 14. Nov 18 40,000 CA$0.09 CA$3,450
08. Nov 18 Buy Steve Loutskou Individual 08. Nov 18 08. Nov 18 42,000 CA$0.09 CA$3,682
09. Nov 18 Buy Shawn Moniz Individual 08. Nov 18 08. Nov 18 6,000 CA$0.09 CA$547
07. Nov 18 Buy Shawn Moniz Individual 07. Nov 18 07. Nov 18 2,000 CA$0.09 CA$185
31. Oct 18 Buy Steve Loutskou Individual 31. Oct 18 31. Oct 18 48,000 CA$0.10 CA$4,740
31. Oct 18 Buy Fusionworx Investment Group Inc. Company 31. Oct 18 31. Oct 18 20,000 CA$0.10 CA$1,947
23. Oct 18 Buy Fusionworx Investment Group Inc. Company 23. Oct 18 23. Oct 18 2,800 CA$0.09 CA$266
22. Oct 18 Buy FourOneSix Inc. Company 22. Oct 18 22. Oct 18 16,000 CA$0.10 CA$1,560
18. Oct 18 Buy Fusionworx Investment Group Inc. Company 17. Oct 18 17. Oct 18 30,000 CA$0.12 CA$3,745
09. Oct 18 Buy Fusionworx Investment Group Inc. Company 05. Oct 18 05. Oct 18 28,000 CA$0.11 CA$3,202
10. Oct 18 Buy Fusionworx Investment Group Inc. Company 10. Oct 18 10. Oct 18 20,000 CA$0.11 CA$2,257
10. Oct 18 Buy FourOneSix Inc. Company 10. Oct 18 10. Oct 18 40,000 CA$0.12 CA$4,700
05. Oct 18 Buy Steve Loutskou Individual 04. Oct 18 04. Oct 18 148,000 CA$0.12 CA$16,950
05. Oct 18 Buy Fusionworx Investment Group Inc. Company 04. Oct 18 04. Oct 18 50,400 CA$0.12 CA$5,793
25. Sep 18 Buy Steve Loutskou Individual 25. Sep 18 25. Sep 18 10,000 CA$0.09 CA$925
25. Sep 18 Buy FourOneSix Inc. Company 25. Sep 18 25. Sep 18 100,000 CA$0.09 CA$9,250
24. Sep 18 Buy Fusionworx Investment Group Inc. Company 21. Sep 18 21. Sep 18 4,000 CA$0.10 CA$390
24. Sep 18 Buy FourOneSix Inc. Company 21. Sep 18 21. Sep 18 120,000 CA$0.10 CA$11,532
X
Management checks
We assess Eurolife Brands's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eurolife Brands has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EURO News

Simply Wall St News

EURO Company Info

Description

Eurolife Brands Inc. operates as a business technology company within the health sciences sector in the United States and internationally. It operates Cannvas.Me, a platform that provides accessible and evidence-based education related to cannabis; and Cannvas Data platform that delivers deeper insights into industry trends, consumer behavior, and pre-purchasing patterns of cannabis consumption. The company was formerly known as Cannvas MedTech Inc. and changed its name to Eurolife Brands Inc. in August 2019. Eurolife Brands Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.

Details
Name: Eurolife Brands Inc.
EURO
Exchange: CNSX
Founded: 2014
CA$34,924,844
349,248,444
Website: http://www.eurolifebrands.com
Address: Eurolife Brands Inc.
750 West Pender Street,
Suite 804,
Vancouver,
British Columbia, V6C 2T7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX EURO Common Shares Canadian National Stock Exchange CA CAD 03. Jul 2018
DB 3CMA Common Shares Deutsche Boerse AG DE EUR 03. Jul 2018
Number of employees
Current staff
Staff numbers
0
Eurolife Brands employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/14 01:11
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.